Table 1.

Characteristics of Studies Included in Meta-Analysis of Standard Dose IMVAMUNE (1×10⁸ TCID₅₀, liquid formulation, subcutaneous needle injection on Days 0 and 28)

Study	Year Completed	Population	Clinical Centers	Total Enrolled	Number With Antibody Measurements	Number Receiving Standard Dose IMVAMUNE	Antibody Measurement Timepoints
NCT 0043702120	2009	Healthy vaccinia-naive adults, Age 18–35, born after 1971	Case Western Reserve University, Cleveland, OH; Duke University, Durham, NC; Saint Louis University, Saint Louis, MO; University of Iowa, Iowa City, IA; University of Maryland, College Park, MD; University of Rochester, Rochester, NY; University of Texas - Galveston, Galveston, TX	226	189	66	Day of Second Vaccination; Day 04; Day 08; Day 14; Day 28; Day 180; Day 365
NCT 0087976222	2011	Healthy vaccinia-naive adults, Age 18–37, born after 1971	Saint Louis University, Saint Louis, MO; University of Iowa, Iowa City, IA	91	91	45	Day of Second Vaccination; Day 14; Day 28; Day 180
NCT 00914732	2011	Healthy vaccinia-naive adults, Age 18–38, born after 1971	Baylor University, Waco, TX; Emory University, Atlanta, GA; Group Health Cooperative, Seattle, WA; Johns Hopkins University, Baltimore, MD; Saint Louis University, Saint Louis, MO; University of Iowa, Iowa City, IA; University of Maryland, College Park, MD; University of Washington, Seattle, WA; Vanderbilt University, Nashville, TN	525	512	164	Day of Second Vaccination; Day 14; Day 28; Day 180